<DOC>
	<DOCNO>NCT01482156</DOCNO>
	<brief_summary>Study two part : 1 . Dose-finding : determine maximum tolerate dose ( MTD ) evaluate safety tolerability RAD001 ( everolimus , Afinitor® ) combination BEZ235 patient advance solid tumor . 2 . Dose-expansion : ass safety tolerability RAD001 BEZ235 MTD patient ER+/HER2- metastatic breast cancer metastatic renal cell cancer</brief_summary>
	<brief_title>Dose Finding Study RAD001 ( Everolimus , Afinitor® ) Combination With BEZ235 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Male female patient age 18 year old In dose finding phase , patient histologically cytologically confirm advanced solid malignancy metastatic unresectable In dose expansion phase , enrollment limit patient : Patients metastatic renal cell carcinoma ( mRCC ) whose disease progress despite prior treatment VEGFRTKI ( vascular endothelial growth factor receptor tyrosine kinase inhibitor ) therapy ( least one two line VEGFRTKI therapy ) Patients metastatic breast cancer ( MBC ) ER+/HER2 , whose disease progress despite prior treatment least one two line chemotherapy least one prior line endocrine therapy metastatic setting WHO performance status 02 Lab parameter within specifically define criterion Patients measurable disease per RECIST 1.0 Patients previously receive mTOR inhibitor PI3K inhibitor Patients CNS metastases unless previously treat surgery , wholebrain radiation stereotactic radiosurgery plus disease stable least 2 month without steroid use least 1 month prior first dose RAD001 BEZ235 . Subjects permit receive enzymeinducing antiepileptic drug . Major surgery within 2 week prior study enrollment Patient take anticancer drug concomitantly Received radiation within 4 week prior study enrollment ( 2 week limited field radiation ) Receive chemotherapy 4 week prior study enrollment Received live attenuate vaccine within 1 week prior study enrollment History HIV Any severe and/or uncontrolled medical condition Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Advanced solid tumor</keyword>
	<keyword>Metastatic renal cell carcinoma ( mRCC )</keyword>
	<keyword>ER+/HER2-Metastatic breast cancer ( MBC )</keyword>
	<keyword>Dose finding study</keyword>
	<keyword>mTOR</keyword>
	<keyword>Pl3K</keyword>
	<keyword>BEZ235</keyword>
	<keyword>RAD001</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Afinitor®</keyword>
	<keyword>ER+/HER2- metastatic breast cancer</keyword>
</DOC>